The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers

References

• Arozal, W, Watanabe, K, Veeraveedu, PT, Ma, M, Thandavarayan, RA, Sukumaran, V, et al. (2010). Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 274:18–26.
   Google Scholar
• Aubel-Sadron, G., Londos-Gagliardi, D. (1984). Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 66:333–352.
   PubMed Web of Science ®Google Scholar
• Belvedere, G., Suarato, A., Geroni, C., Giuliani, F. C., D’Incalci, M. (1989). Comparison of intracellular drug retention, DNA damage, and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo). Biochem Pharmacol 38:3713–3721.
   Google Scholar
• Berg, J. W., Hutter, R. V. (1995). Breast cancer. Cancer 75:257–269.
   PubMedGoogle Scholar
• Bodley, A, Liu, LF, Israel, M, Seshadri, R, Koseki, Y, Giuliani, FC, et al. (1989). DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 49:5969–5978.
   PubMed Web of Science ®Google Scholar
• Ciesielska, E., Studzian, K., Wasowska, M., Oszczapowicz, I., Szmigiero, L. (2005). Cytotoxicity, cellular uptake, and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety. Cell Biol Toxicol 21:139–147.
   PubMed Web of Science ®Google Scholar
• Criscitiello, C., Fumagalli, D., Saini, K. S., Loi, S. (2010). Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. Onco Targets Ther 4:1–11.
   PubMedGoogle Scholar
• Dano, K., Frederiksen, S., Hellung-Larsen, P. (1972). Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res 32:1307–1314.
   Google Scholar
• Di Nicolantonio, F., Mercer, S. J., Knight, L. A., Gabriel, F. G.., Whitehouse, P. A., Sharma, S., et al. (2005). Cancer cell adaptation to chemotherapy. BMC Cancer 5:78.
   Google Scholar
• Du, J, Lu, WL, Ying, X, Liu, Y, Du, P, Tian, W, et al. (2009). Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm 6:905–917.
   PubMed Web of Science ®Google Scholar
• Guo, J., Zhou, J., Ying, X., Men, Y., Li, R. J., Zhang, Y., et al. (2010). Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. J Pharm Pharm Sci 13:136–151.
   PubMed Web of Science ®Google Scholar
• Goldenberg, G. J., Froese, E. K. (1985). Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol 34:763–770.
   PubMed Web of Science ®Google Scholar
• Haran, G., Cohen, R., Bar, L. K., Barenholz, Y. (1993). Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151:201–215.
   PubMed Web of Science ®Google Scholar
• Hegedus, C, Ozvegy-Laczka, C, Apati, A, Magocsi, M, Nemet, K, Orfi, L, et al. (2009). Interaction of nilotinib, dasatinib, and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158:1153–1164.
   PubMed Web of Science ®Google Scholar
• Hulhoven, R. (1978). Daunorubicin, daunorubicinol, and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit. Biomedicine 29:164–167.
   PubMedGoogle Scholar
• Kayyali, R., Marriott, C., Wiseman, H. (1994). Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells? FEBS Lett 344:221–224.
   PubMed Web of Science ®Google Scholar
• Lecompte, M. F., Laurent, G., Jaffrezou, J. P. (2002). Sphingomyelin content conditions insertion of daunorubicin within phosphatidylcholine monolayers. FEBS Lett 525:141–144.
   PubMed Web of Science ®Google Scholar
• Leslie, K. K., Koil, C., Rayburn, W. F. (2005). Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am 32:627–640.
   PubMed Web of Science ®Google Scholar
• Liang, YG, Jorgensen, AG, Kaestel, CG, Wiencke, AK, Lui, GM, la Cour, MH, et al. (2000). Bcl-2, Bax, and c-Fos expression correlates to RPE cell apoptosis induced by UV-light and daunorubicin. Curr Eye Res 20:25–34.
   Web of Science ®Google Scholar
• Licht, T., Fiebig, H. H., Bross, K. J., Herrmann, F., Berger, D. P., Shoemaker, R., et al. (1991). Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 49:630–637.
   Google Scholar
• Liscovitch, M., Lavie, Y. (2002). Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5:349–355
   PubMedGoogle Scholar
• Mankhetkorn, S., Dubru, F., Hesschenbrouck, J., Fiallo, M., Garnier-Suillerot, A. (1996). Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol Pharmacol 49:532–539.
   PubMed Web of Science ®Google Scholar
• Marbeuf-Gueye, C., Salerno, M., Quidu, P., Garnier-Suillerot, A. (2000). Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. Eur J Pharmacol 391:207–216.
   PubMed Web of Science ®Google Scholar
• Meriwether, W. D., Bachur, N. R. (1972). Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res 32:1137–1142.
   PubMed Web of Science ®Google Scholar
• Pallarés-Trujillo, J., López-Soriano, F. J., Argilés, J. M. (2000). Lipids: a key role in multidrug resistance? (Review). Int J Oncol 16:783–798.
   Google Scholar
• Panasci, L., Jean-Claude, B. J., Vasilescu, D., Mustafa, A., Damian, S., Damian, Z., et al. (1996). Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochem Pharmacol 52:1097–1102.
   PubMed Web of Science ®Google Scholar
• Sadzuka, Y., Hatakeyama, H., Sonobe, T. (2010). Enhancement of doxorubicin concentration in the M5076 ovarian sarcoma cells by cucurbitacin E co-treatment. Int J Pharm 383:186–191.
   PubMedGoogle Scholar
• Sargent, J. M., Williamson, C. J., Maliepaard, M., Elgie, A. W., Scheper, R. J., Taylor, C. G. (2001). Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115:257–262.
   PubMed Web of Science ®Google Scholar
• Shadle, S. E., Bammel, B. P., Cusack, B. J., Knighton, R. A., Olson, S. J., Mushlin, P. S., et al. (2000). Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol 60:1435–1444.
   PubMed Web of Science ®Google Scholar
• Tiwari, A. K., Sodani, K., Dai, C. L., Ashby, C. R. Jr, Chen, Z. S. (2011). Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 11:570–594.
   Google Scholar
• Turk, D., Szakacs, G. (2009). Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel 12:246–252.
   PubMed Web of Science ®Google Scholar
• Vara-Salazar Ede, L., Suárez-López, L., Angeles-Llerenas, A., Torres-Mejía, G., Lazcano-Ponce, E. (2011). Breast cancer mortality trends in Mexico, 1980–2009. Salud Publica Mex 53:385–393.
   Google Scholar
• Wiseman, H. (1994). Tamoxifen and estrogens as membrane antioxidants: comparison with cholesterol. Methods Enzymol 234:590–602.
   Google Scholar
• Ying, X., Wen, H., Yao, H. J., Zhang, Y., Tian, W., Zhang, L., et al. (2011). Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Pharmacology 87:105–114.
   PubMed Web of Science ®Google Scholar
• Zhigaltsev, I. V., Kaplun, A. P., Kucheryanu, V. G., Kryzhanovsky, G. N., Kolomeichuk, S. N., Shvets, V. I., et al. (2001). Liposomes containing dopamine entrapped in response to transmembrane ammonium sulfate gradient as carrier system for dopamine delivery into the brain of parkinsonian mice. J liposome Res 11:55–71.
   PubMed Web of Science ®Google Scholar